Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium
UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced... Read More
Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action
UF Innovate | Sid Martin Biotech client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective... Read More
BSI Team Joins Forces With Oragenics in Search for New Antibiotics
A biophysics team led by Florida International University researchers Prem Chapagain and Bernard Gerstman has joined forces with UF Innovate | Sid... Read More
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
UF Innovate | Sid Martin Biotech resident client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
Oragenics, Inc. Receives Further Validation for Lantibiotic Compound OG716
UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”),... Read More
Oragenics Receives Approval for Phase 2 Study (Pharmacy Choice)
UF Innovate | Sid Martin Biotech alumni startup Oragenics announced that it has been approved in Belgium to enroll patients in its... Read More
Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review (Business Wire)
UF Innovate | Sid Martin alumni startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective... Read More
Oragenics Touts New Drug to Fight Clostridium Difficile (Proactive Investors)
New research by Sid Martin Biotech alum Oragenics Inc., now a Tampa-based clinical-stage biotech group, has uncovered a novel type of antibiotic... Read More
